BridgeBio Pharma (BBIO) Equity Income (2018 - 2026)

BridgeBio Pharma has disclosed Equity Income across 5 years of filings, most recently posting -$18.3 million for Q1 2026.

• Equity Income for Q1 2026 came in at -$18.3 million, down 17.53% year-over-year; the trailing twelve-month figure through Mar 2026 was -$75.3 million (down 95.45% YoY), and the FY2025 annual result was -$72.6 million, down 132.84% from the prior year.
• Equity Income came in at -$18.3 million for Q1 2026 at BridgeBio Pharma, up from -$21.0 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of -$6.6 million in Q3 2024 to a low of -$21.0 million in Q4 2025.
• The 3-year median for Equity Income is -$15.7 million (2025), against an average of -$14.2 million.
• Across the five-year window, Equity Income sank 154.75% in 2025 and declined 17.53% in 2026, its largest moves.
• BridgeBio Pharma's Equity Income stood at -$8.5 million in 2024, then sank by 147.4% to -$21.0 million in 2025, then gained by 13.06% to -$18.3 million in 2026.
• The last three Equity Income figures came in at -$18.3 million (Q1 2026), -$21.0 million (Q4 2025), and -$15.8 million (Q3 2025), per Business Quant data.